256 related articles for article (PubMed ID: 15273729)
1. Direct FGF receptor 1 activation through an anti-idiotypic strategy mimicks the biological activity of FGF-2 and inhibits the progression of the bladder carcinoma derived from NBT-II cells.
Malavaud B; Pedron S; Sordello S; Mazerolles C; Billottet C; Thiery JP; Jouanneau J; Plouët J
Oncogene; 2004 Sep; 23(40):6769-78. PubMed ID: 15273729
[TBL] [Abstract][Full Text] [Related]
2. Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2.
Billottet C; Janji B; Thiery JP; Jouanneau J
Oncogene; 2002 Nov; 21(53):8128-39. PubMed ID: 12444548
[TBL] [Abstract][Full Text] [Related]
3. FGF-2 and FGF-1 expressed in rat bladder carcinoma cells have similar angiogenic potential but different tumorigenic properties in vivo.
Jouanneau J; Plouet J; Moens G; Thiery JP
Oncogene; 1997 Feb; 14(6):671-6. PubMed ID: 9038374
[TBL] [Abstract][Full Text] [Related]
4. Deregulation of Flk-1/vascular endothelial growth factor receptor-2 in fibroblast growth factor receptor-1-deficient vascular stem cell development.
Magnusson P; Rolny C; Jakobsson L; Wikner C; Wu Y; Hicklin DJ; Claesson-Welsh L
J Cell Sci; 2004 Mar; 117(Pt 8):1513-23. PubMed ID: 15020678
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms.
Auguste P; Gürsel DB; Lemière S; Reimers D; Cuevas P; Carceller F; Di Santo JP; Bikfalvi A
Cancer Res; 2001 Feb; 61(4):1717-26. PubMed ID: 11245488
[TBL] [Abstract][Full Text] [Related]
6. Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype.
Ortéga N; Jonca F; Vincent S; Favard C; Ruchoux MM; Plouët J
Am J Pathol; 1997 Nov; 151(5):1215-24. PubMed ID: 9358746
[TBL] [Abstract][Full Text] [Related]
7. Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis.
Giavazzi R; Sennino B; Coltrini D; Garofalo A; Dossi R; Ronca R; Tosatti MP; Presta M
Am J Pathol; 2003 Jun; 162(6):1913-26. PubMed ID: 12759248
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor 1-induced differentiation of endothelial cell line established from tsA58 large T transgenic mice.
Kanda S; Landgren E; Ljungström M; Claesson-Welsh L
Cell Growth Differ; 1996 Mar; 7(3):383-95. PubMed ID: 8838868
[TBL] [Abstract][Full Text] [Related]
9. Signaling via fibroblast growth factor receptor-1 is dependent on extracellular matrix in capillary endothelial cell differentiation.
Kanda S; Tomasini-Johansson B; Klint P; Dixelius J; Rubin K; Claesson-Welsh L
Exp Cell Res; 1999 Apr; 248(1):203-13. PubMed ID: 10094827
[TBL] [Abstract][Full Text] [Related]
10. A short peptide domain of platelet factor 4 blocks angiogenic key events induced by FGF-2.
Hagedorn M; Zilberberg L; Lozano RM; Cuevas P; Canron X; Redondo-Horcajo M; Gimenez-Gallego G; Bikfalvi A
FASEB J; 2001 Mar; 15(3):550-2. PubMed ID: 11259363
[TBL] [Abstract][Full Text] [Related]
11. Nuclear 24 kD fibroblast growth factor (FGF)-2 confers metastatic properties on rat bladder carcinoma cells.
Okada-Ban M; Moens G; Thiery JP; Jouanneau J
Oncogene; 1999 Nov; 18(48):6719-24. PubMed ID: 10597279
[TBL] [Abstract][Full Text] [Related]
12. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation.
Freeman KW; Gangula RD; Welm BE; Ozen M; Foster BA; Rosen JM; Ittmann M; Greenberg NM; Spencer DM
Cancer Res; 2003 Oct; 63(19):6237-43. PubMed ID: 14559809
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice.
Arbeit JM; Olson DC; Hanahan D
Oncogene; 1996 Nov; 13(9):1847-57. PubMed ID: 8934530
[TBL] [Abstract][Full Text] [Related]
14. The community effect in FGF-1 mediated tumor progression of a rat bladder carcinoma does not involve a direct paracrine signaling.
Jouanneau J; Moens G; Thiery JP
Oncogene; 1999 Jan; 18(2):327-33. PubMed ID: 9927189
[TBL] [Abstract][Full Text] [Related]
15. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
16. Chemotactic migration of mesencephalic neural crest cells in the mouse.
Kubota Y; Ito K
Dev Dyn; 2000 Feb; 217(2):170-9. PubMed ID: 10706141
[TBL] [Abstract][Full Text] [Related]
17. Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis.
Aviezer D; Cotton S; David M; Segev A; Khaselev N; Galili N; Gross Z; Yayon A
Cancer Res; 2000 Jun; 60(11):2973-80. PubMed ID: 10850445
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor.
Ogawa T; Takayama K; Takakura N; Kitano S; Ueno H
Cancer Gene Ther; 2002 Aug; 9(8):633-40. PubMed ID: 12136423
[TBL] [Abstract][Full Text] [Related]
20. Activation of FGF receptors by mutations in the transmembrane domain.
Li Y; Mangasarian K; Mansukhani A; Basilico C
Oncogene; 1997 Mar; 14(12):1397-406. PubMed ID: 9136983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
